Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in the course of Parkinson's disease (PD), and therefore, most PD patients receive antidepressant drugs. Agomelatine is a recently introduced antidepressant drug acting as an MT1/MT2 melatonergic receptor agonist and 5HT2C/5HT2B serotonergic antagonist. The aim of this case series was to evaluate the role of agomelatine in the treatment of MDD associated with PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.neuropsych.12110286 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Agomelatine bears promising potential in treating bipolar depression- a systematic review.
Int J Psychiatry Clin Pract
December 2024
Department of Psychiatry, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Introduction: The controversy of antidepressant use in bipolar depression remains controversial. Agomelatine (AGO) is an effective antidepressant in major depressive disorder (MDD), but its application in bipolar depression was little discussed. We aimed to provide a comprehensive systematic review of clinical evidence from studies examining the efficacy and safety of AGO for bipolar depression.
View Article and Find Full Text PDFEfficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis.
Int J Mol Sci
November 2024
Department of Pharmacology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
Major depressive disorder (MDD) and diabetes mellitus (DM) remain among the most prevalent diseases and the most significant challenges faced by medicine in the 21st century. The frequent co-occurrence and bidirectional relationship between the two conditions necessitates the identification of treatment strategies that benefit both. The purpose of this study was to systematically review and meta-analyze data on the efficacy and safety of agomelatine (AGO) in the treatment of patients with depression with comorbid diabetes to explore its potential mechanism of action in both diseases and its impact on diabetic parameters.
View Article and Find Full Text PDFAgomelatine as Antidepressant Treatment in Elderly Patients With Previous Hyponatremia Due To SSRI Use: Case Series.
Hum Psychopharmacol
January 2025
Departamento de Psiquiatría, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Objective: To evaluate agomelatine treatment in elderly patients with major depressive disorder (MDD) who developed hyponatremia while using selective serotonin receptor inhibitors (SSRIs).
Methods: Patients (60 years or older) with hyponatremia after SSRI treatment for MDD were changed to agomelatine 50 mg/day during one month to observe sodium levels during the treatment and change in depressive symptoms. Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale (CGI) of severity were used before and after treatment with agomelatine.
An Experimental Insight Into the Role of Agomelatine in Renal Ischemia/Reperfusion Injury.
J Biochem Mol Toxicol
December 2024
Department of Physiology, Faculty of Medicine, İnönü University, Malatya, Turkey.
Acute kidney injury (AKI) is one of the leading causes of chronic kidney disease and accounts for 50%-75% of mortality following renal pathologies or organ transplantation. Ischemia‒reperfusion injury (IRI) involves an interrupted blood supply to organs and the kidney; IRI exacerbates AKI development. Owing to several pharmacological treatment methods, AKI still has a poor prognosis, and novel therapeutic options are needed.
View Article and Find Full Text PDFEfficacy of Melatonin as a Promising Intervention for Migraine Prevention: A Systematic Review of Randomized Control Trials.
Cureus
October 2024
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Article Synopsis
- The use of melatonin as an over-the-counter supplement has increased due to more people experiencing sleep-wake disorders, especially during the post-COVID-19 era.
- This systematic review investigates the effectiveness and side effects of melatonin for migraine prevention, comparing it to standard treatments and placebos, based on data from seven high-quality randomized control trials with 1,283 participants.
- Findings suggest that melatonin may significantly reduce migraine frequency and severity, though its specific dosage and additional benefits, such as weight control, need further investigation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!